Insider Trading: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

44.35USD
12 Sep 2014
Price Change (% chg)

$-0.24 (-0.54%)
Prev Close
$44.59
Open
$44.50
Day's High
$44.77
Day's Low
$44.10
Volume
602,180
Avg. Vol
753,262
52-wk High
$54.25
52-wk Low
$29.36

Search Stocks
BIBERSTEIN KATHRYN L Options Exercised: 0
Trade Date: Wednesday, 30 Jan 2013 Price: 23.13
Title: General Counsel Shares Held: 42,665
Type Traded: Direct Net Change in Shares This Filing: 0

Institutional Holders

% Shares Owned: 97.39%
# of Holders: 288
Total Shares Held: 142,028,570
3 Mo. Net Change: 3,036,294
# New Positions: 28
# Closed Positions: 29
# Increased Positions: 127
# Reduced Positions: 135
# Net Buyers: -8

Officers & Directors

Name Age Since Current Position

Richard Pops

52 2011 Chairman of the Board, Chief Executive Officer

Shane Cooke

51 2011 President

James Frates

47 2011 Chief Financial Officer, Senior Vice President

Gordon Pugh

55 2011 Chief Operating Officer, Senior Vice President, Chief Risk Officer

Kathryn Biberstein

54 2011 Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

Rebecca Peterson

38 Senior Vice President

James Botkin

64 2011 Senior Vice President - Operations

Elliot Ehrich

54 2011 Senior Vice President - Research and Development, Chief Medical Officer

Michael Landine

60 2011 Senior Vice President - Corporate Development

Srdjan Stankovic

56 2013 Senior Vice President - Clinical Development

Mark Stejbach

50 2012 Senior Vice President, Chief Commercial Officer

Peter Norman

2013 Vice President - Government Affairs and Policy

Paul Mitchell

60 2012 Lead Independent Director

Nancy Wysenski

56 2013 Director

David Anstice

65 2011 Independent Director

Floyd Bloom

76 2011 Independent Director

Robert Breyer

69 2011 Independent Director

Wendy Dixon

58 2011 Independent Director

Geraldine Henwood

59 2011 Independent Director
Search Stocks